TLC Submits Investigational New Drug (IND) Application to the Taiwan Food and Drug Administration (TFDA) for TLC19 Inhalable Liposomal Hydroxychloroquine for COVID-19
We look forward to the prompt initiation of a Phase I clinical trial to enroll healthy volunteers in Taiwan to collect pharmacokinetic and safety data on a new liposome formulation with the new inhalation route.
Data from this trial will serve as a sound basis for subsequent dose estimation in patients with COVID-19, who will be the subjects of our Phase II/III clinical trials, scheduled to take place in the United States and other countries impacted the hardest by the pandemic.
finance.yahoo.c...-103000609.html?guce_refer...
seekingalpha.com/new...ug-for-covidminus-19
We look forward to the prompt initiation of a Phase I clinical trial to enroll healthy volunteers in Taiwan to collect pharmacokinetic and safety data on a new liposome formulation with the new inhalation route.
Data from this trial will serve as a sound basis for subsequent dose estimation in patients with COVID-19, who will be the subjects of our Phase II/III clinical trials, scheduled to take place in the United States and other countries impacted the hardest by the pandemic.
finance.yahoo.c...-103000609.html?guce_refer...
seekingalpha.com/new...ug-for-covidminus-19